Please assess the completion status of the following clinical trial:

Trial Title: Humoral Response to Tick-borne Encephalitis Vaccine in Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years or more~* generally healthy~* no immunosuppressive condition~* fertile women must use contraceptives~Exclusion Criteria:~* Previous TBE infection~* Previously immunized with TBE vaccine~* Anaphylactic reaction to egg protein~* Any disease or therapy which might suppress the immune response~* Vaccination should be delayed if a participant has fever

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TBE vaccine at 0+30 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will follow the standard recommendation and will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 days during the first year and an additional dose one year later
- TBE vaccine at 0+7+21 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 7 +21 days during the first year and an additional dose one year later
- TBE vaccinte at 0+30+90 days (Type: ACTIVE_COMPARATOR): This group of 50 participants will will be given TBE vaccine 0.5 ml FSME immune at 0 + 30 + 90 days during the first year and an additional dose one year later
- younger participants (Type: ACTIVE_COMPARATOR): This group of 50 participants in the age group 18-49 years will be given TBE vaccine 0.5 ml FSME immune at 0 +30 days during the first year and an additional dose one year later

Based on this trial design, predict the completion outcome and termination type (if applicable).